{"id":66483,"date":"2026-05-27T21:10:58","date_gmt":"2026-05-27T13:10:58","guid":{"rendered":"https:\/\/flcube.com\/?p=66483"},"modified":"2026-05-27T21:10:59","modified_gmt":"2026-05-27T13:10:59","slug":"changchun-high-new-technology-industries-subsidiary-secures-nmpa-approval-for-gensci144-novel-oral-pku-treatment-targeting-slc6a19-transporter","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=66483","title":{"rendered":"Changchun High &amp; New Technology Industries Subsidiary Secures NMPA Approval for GenSci144, Novel Oral PKU Treatment Targeting SLC6A19 Transporter"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Changchun High &amp; New Technology Industries (Group) Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/000661:SHE\">SHE: 000661<\/a>) announced that its subsidiary <strong>Changchun GeneScience Pharmaceutical Inc.<\/strong> has received clinical trial approval from China&#8217;s <strong>National Medical Products Administration (NMPA)<\/strong> for <strong>GenSci144<\/strong>, a <strong>Category 1 chemical drug<\/strong> designated for the treatment of <strong>phenylketonuria (PKU)<\/strong>.<\/p>\n\n\n\n<h2 id=\"h-regulatory-milestone\" class=\"wp-block-heading\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Parent Company<\/strong><\/td><td>Changchun High &amp; New Technology Industries (Group) Inc. (SHE: 000661)<\/td><\/tr><tr><td><strong>Subsidiary<\/strong><\/td><td>Changchun GeneScience Pharmaceutical Inc.<\/td><\/tr><tr><td><strong>Drug Candidate<\/strong><\/td><td>GenSci144 (Category 1 chemical drug)<\/td><\/tr><tr><td><strong>Regulatory Authority<\/strong><\/td><td>National Medical Products Administration (NMPA)<\/td><\/tr><tr><td><strong>Approval Type<\/strong><\/td><td>Clinical trial approval granted<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Phenylketonuria (PKU)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-disease-background-amp-unmet-need\" class=\"wp-block-heading\">Disease Background &amp; Unmet Need<\/h2>\n\n\n\n<h3 id=\"h-phenylketonuria-pku-overview\" class=\"wp-block-heading\">Phenylketonuria (PKU) Overview<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Genetic Basis:<\/strong> Autosomal recessive disorder caused by <strong>PAH gene defects<\/strong><\/li>\n\n\n\n<li><strong>Pathophysiology:<\/strong> Deficiency in <strong>phenylalanine hydroxylase (PAH) activity<\/strong> leading to impaired phenylalanine metabolism<\/li>\n\n\n\n<li><strong>Clinical Consequence:<\/strong> <strong>Hyperphenylalaninemia (HPA)<\/strong> \u2013 elevated blood phenylalanine levels causing neurological damage if untreated<\/li>\n\n\n\n<li><strong>Current Treatment Limitations:<\/strong> Existing therapies depend on residual PAH enzyme activity, excluding many severe PKU patients<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-gensci144-mechanism-of-action\" class=\"wp-block-heading\">GenSci144 Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule Type:<\/strong> Oral small-molecule inhibitor<\/li>\n\n\n\n<li><strong>Target:<\/strong> <strong>Neutral amino acid transporter SLC6A19<\/strong><\/li>\n\n\n\n<li><strong>Primary Mechanism:<\/strong> Inhibits <strong>SLC6A19-mediated renal tubular reabsorption of phenylalanine<\/strong><\/li>\n\n\n\n<li><strong>Therapeutic Effect:<\/strong> Reduces blood phenylalanine levels through enhanced urinary excretion<\/li>\n\n\n\n<li><strong>Key Innovation:<\/strong> <strong>Independent of residual PAH enzyme activity<\/strong>, potentially applicable to broader PKU patient population<\/li>\n\n\n\n<li><strong>Combination Potential:<\/strong> Compatible with existing treatment regimens for synergistic effect<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-advantages-amp-market-opportunity\" class=\"wp-block-heading\">Strategic Advantages &amp; Market Opportunity<\/h2>\n\n\n\n<h3 id=\"h-patient-population-expansion\" class=\"wp-block-heading\">Patient Population Expansion<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Broader Applicability:<\/strong> Treats patients regardless of PAH mutation severity or residual enzyme function<\/li>\n\n\n\n<li><strong>Severe PKU Coverage:<\/strong> Addresses previously untreatable patient subpopulations<\/li>\n\n\n\n<li><strong>Pediatric Focus:<\/strong> Potential for early intervention to prevent neurological complications<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-commercial-differentiation\" class=\"wp-block-heading\">Commercial Differentiation<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Oral Administration:<\/strong> Superior convenience compared to injectable or dietary restriction approaches<\/li>\n\n\n\n<li><strong>Novel Target:<\/strong> First-in-class approach targeting renal phenylalanine handling rather than hepatic metabolism<\/li>\n\n\n\n<li><strong>Category 1 Status:<\/strong> Highest innovation classification in China&#8217;s regulatory framework<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-market-context\" class=\"wp-block-heading\">Market Context<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Global PKU Prevalence:<\/strong> Approximately 1 in 10,000-15,000 live births worldwide<\/li>\n\n\n\n<li><strong>China Patient Population:<\/strong> Estimated 15,000-20,000 PKU patients requiring lifelong treatment<\/li>\n\n\n\n<li><strong>Treatment Gap:<\/strong> Significant unmet need for effective therapies in severe and non-responsive cases<\/li>\n\n\n\n<li><strong>Pricing Premium:<\/strong> Novel mechanism and broad applicability support premium pricing strategy<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-development-pathway-amp-timeline\" class=\"wp-block-heading\">Development Pathway &amp; Timeline<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Current Stage:<\/strong> IND approval granted \u2013 Phase I studies expected to initiate Q3-Q4 2026<\/li>\n\n\n\n<li><strong>Clinical Strategy:<\/strong> Initial safety and pharmacokinetic studies followed by proof-of-concept in PKU patients<\/li>\n\n\n\n<li><strong>Regulatory Path:<\/strong> Potential accelerated approval pathway given orphan disease designation and Category 1 status<\/li>\n\n\n\n<li><strong>International Potential:<\/strong> Platform technology may support global development following Chinese validation<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical development timelines, regulatory approvals, and market expectations for GenSci144. Actual results may differ due to risks including clinical trial outcomes, regulatory decisions, competitive dynamics, and market access challenges.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/\u957f\u6625\u9ad8\u65b0\uff1a\u5173\u4e8e\u5b50\u516c\u53f8GenSci144\u7247\u5883\u5185\u751f\u4ea7\u836f\u54c1\u6ce8\u518c\u4e34\u5e8a\u8bd5\u9a8c\u7533\u8bf7\u83b7\u5f97\u6279\u51c6\u7684\u516c\u544a.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of \u957f\u6625\u9ad8\u65b0\uff1a\u5173\u4e8e\u5b50\u516c\u53f8GenSci144\u7247\u5883\u5185\u751f\u4ea7\u836f\u54c1\u6ce8\u518c\u4e34\u5e8a\u8bd5\u9a8c\u7533\u8bf7\u83b7\u5f97\u6279\u51c6\u7684\u516c\u544a.\"><\/object><a id=\"wp-block-file--media-ec0e6e12-3dcd-40d0-b269-193b5f6e1709\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/\u957f\u6625\u9ad8\u65b0\uff1a\u5173\u4e8e\u5b50\u516c\u53f8GenSci144\u7247\u5883\u5185\u751f\u4ea7\u836f\u54c1\u6ce8\u518c\u4e34\u5e8a\u8bd5\u9a8c\u7533\u8bf7\u83b7\u5f97\u6279\u51c6\u7684\u516c\u544a.pdf\">\u957f\u6625\u9ad8\u65b0\uff1a\u5173\u4e8e\u5b50\u516c\u53f8GenSci144\u7247\u5883\u5185\u751f\u4ea7\u836f\u54c1\u6ce8\u518c\u4e34\u5e8a\u8bd5\u9a8c\u7533\u8bf7\u83b7\u5f97\u6279\u51c6\u7684\u516c\u544a<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/\u957f\u6625\u9ad8\u65b0\uff1a\u5173\u4e8e\u5b50\u516c\u53f8GenSci144\u7247\u5883\u5185\u751f\u4ea7\u836f\u54c1\u6ce8\u518c\u4e34\u5e8a\u8bd5\u9a8c\u7533\u8bf7\u83b7\u5f97\u6279\u51c6\u7684\u516c\u544a.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-ec0e6e12-3dcd-40d0-b269-193b5f6e1709\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Changchun High &amp; New Technology Industries (Group) Inc. (SHE: 000661) announced that its subsidiary Changchun&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[2929,62,358,24,1171],"class_list":["post-66483","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-changchun-high-new-technology-industries","tag-clinical-trial-approval-initiation","tag-genescience-pharmaceutical","tag-rare-orphan-disease-drugs","tag-she-000661"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.7) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Changchun High &amp; New Technology Industries Subsidiary Secures NMPA Approval for GenSci144, Novel Oral PKU Treatment Targeting SLC6A19 Transporter - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Changchun High &amp; New Technology Industries (Group) Inc. (SHE: 000661) announced that its subsidiary Changchun GeneScience Pharmaceutical Inc. has received clinical trial approval from China&#039;s National Medical Products Administration (NMPA) for GenSci144, a Category 1 chemical drug designated for the treatment of phenylketonuria (PKU).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=66483\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Changchun High &amp; New Technology Industries Subsidiary Secures NMPA Approval for GenSci144, Novel Oral PKU Treatment Targeting SLC6A19 Transporter\" \/>\n<meta property=\"og:description\" content=\"Changchun High &amp; New Technology Industries (Group) Inc. (SHE: 000661) announced that its subsidiary Changchun GeneScience Pharmaceutical Inc. has received clinical trial approval from China&#039;s National Medical Products Administration (NMPA) for GenSci144, a Category 1 chemical drug designated for the treatment of phenylketonuria (PKU).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=66483\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-27T13:10:58+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-27T13:10:59+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66483#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66483\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Changchun High &amp; New Technology Industries Subsidiary Secures NMPA Approval for GenSci144, Novel Oral PKU Treatment Targeting SLC6A19 Transporter\",\"datePublished\":\"2026-05-27T13:10:58+00:00\",\"dateModified\":\"2026-05-27T13:10:59+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66483\"},\"wordCount\":442,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Changchun High &amp; New Technology Industries\",\"Clinical trial approval \\\/ initiation\",\"GeneScience Pharmaceutical\",\"Rare \\\/ orphan disease drugs\",\"SHE: 000661\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=66483#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66483\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=66483\",\"name\":\"Changchun High &amp; New Technology Industries Subsidiary Secures NMPA Approval for GenSci144, Novel Oral PKU Treatment Targeting SLC6A19 Transporter - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-05-27T13:10:58+00:00\",\"dateModified\":\"2026-05-27T13:10:59+00:00\",\"description\":\"Changchun High & New Technology Industries (Group) Inc. (SHE: 000661) announced that its subsidiary Changchun GeneScience Pharmaceutical Inc. has received clinical trial approval from China's National Medical Products Administration (NMPA) for GenSci144, a Category 1 chemical drug designated for the treatment of phenylketonuria (PKU).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66483#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=66483\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66483#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Changchun High &amp; New Technology Industries Subsidiary Secures NMPA Approval for GenSci144, Novel Oral PKU Treatment Targeting SLC6A19 Transporter\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Changchun High &amp; New Technology Industries Subsidiary Secures NMPA Approval for GenSci144, Novel Oral PKU Treatment Targeting SLC6A19 Transporter - Insight, China&#039;s Pharmaceutical Industry","description":"Changchun High & New Technology Industries (Group) Inc. (SHE: 000661) announced that its subsidiary Changchun GeneScience Pharmaceutical Inc. has received clinical trial approval from China's National Medical Products Administration (NMPA) for GenSci144, a Category 1 chemical drug designated for the treatment of phenylketonuria (PKU).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=66483","og_locale":"en_US","og_type":"article","og_title":"Changchun High &amp; New Technology Industries Subsidiary Secures NMPA Approval for GenSci144, Novel Oral PKU Treatment Targeting SLC6A19 Transporter","og_description":"Changchun High & New Technology Industries (Group) Inc. (SHE: 000661) announced that its subsidiary Changchun GeneScience Pharmaceutical Inc. has received clinical trial approval from China's National Medical Products Administration (NMPA) for GenSci144, a Category 1 chemical drug designated for the treatment of phenylketonuria (PKU).","og_url":"https:\/\/flcube.com\/?p=66483","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-05-27T13:10:58+00:00","article_modified_time":"2026-05-27T13:10:59+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=66483#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=66483"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Changchun High &amp; New Technology Industries Subsidiary Secures NMPA Approval for GenSci144, Novel Oral PKU Treatment Targeting SLC6A19 Transporter","datePublished":"2026-05-27T13:10:58+00:00","dateModified":"2026-05-27T13:10:59+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=66483"},"wordCount":442,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Changchun High &amp; New Technology Industries","Clinical trial approval \/ initiation","GeneScience Pharmaceutical","Rare \/ orphan disease drugs","SHE: 000661"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=66483#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=66483","url":"https:\/\/flcube.com\/?p=66483","name":"Changchun High &amp; New Technology Industries Subsidiary Secures NMPA Approval for GenSci144, Novel Oral PKU Treatment Targeting SLC6A19 Transporter - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-05-27T13:10:58+00:00","dateModified":"2026-05-27T13:10:59+00:00","description":"Changchun High & New Technology Industries (Group) Inc. (SHE: 000661) announced that its subsidiary Changchun GeneScience Pharmaceutical Inc. has received clinical trial approval from China's National Medical Products Administration (NMPA) for GenSci144, a Category 1 chemical drug designated for the treatment of phenylketonuria (PKU).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=66483#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=66483"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=66483#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Changchun High &amp; New Technology Industries Subsidiary Secures NMPA Approval for GenSci144, Novel Oral PKU Treatment Targeting SLC6A19 Transporter"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66483","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=66483"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66483\/revisions"}],"predecessor-version":[{"id":66485,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66483\/revisions\/66485"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=66483"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=66483"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=66483"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}